About Cancer Genetics (NASDAQ:CGIX)
Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, India, and China. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company's clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. Its biopharma services offer companies with customized solutions for patient stratification and treatment selection through a suite of molecular- and biomarker-based testing services, customized assay development, and trial design consultation. The company's discovery services provide the tools and testing methods for companies and researchers to identify new molecular-based biomarkers for disease. It serves hospitals, cancer centers, clinics, academic institutions, and government-sponsored research institutions, as well as pharmaceutical and biotech companies performing clinical trials. The company collaborates with oncology centers and community-based hospitals to develop its proprietary diagnostic tests. Cancer Genetics, Inc. was founded in 1999 and is based in Rutherford, New Jersey.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CGIX
CUSIPN/A
Phone201-528-9200
Debt
Debt-to-Equity Ratio0.02%
Current Ratio1.18%
Quick Ratio1.18%
Price-To-Earnings
Trailing P/E Ratio-1.39
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$29.12 million
Price / Sales1.05
Cash FlowN/A
Price / CashN/A
Book Value$0.97 per share
Price / Book1.13
Profitability
EPS (Most Recent Fiscal Year)($0.79)
Net Income$-20,880,000.00
Net Margins-71.75%
Return on Equity-66.71%
Return on Assets-34.12%
Miscellaneous
Employees245
Outstanding Shares27,750,000
Cancer Genetics (NASDAQ:CGIX) Frequently Asked Questions
What is Cancer Genetics' stock symbol?
Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."
How were Cancer Genetics' earnings last quarter?
Cancer Genetics, Inc. (NASDAQ:CGIX) released its earnings results on Thursday, May, 11th. The medical research company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $0.07. The medical research company had revenue of $7 million for the quarter, compared to the consensus estimate of $7.62 million. Cancer Genetics had a negative return on equity of 66.71% and a negative net margin of 71.75%. The firm's revenue for the quarter was up 14.8% compared to the same quarter last year. During the same period last year, the business earned ($0.39) earnings per share. View Cancer Genetics' Earnings History.
What price target have analysts set for CGIX?
4 equities research analysts have issued 12-month price objectives for Cancer Genetics' shares. Their forecasts range from $6.00 to $6.00. On average, they expect Cancer Genetics' stock price to reach $6.00 in the next twelve months. View Analyst Ratings for Cancer Genetics.
What are Wall Street analysts saying about Cancer Genetics stock?
Here are some recent quotes from research analysts about Cancer Genetics stock:
- 1. According to Zacks Investment Research, "Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also offers non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Cancer Genetics, Inc. is headquartered in Rutherford, New Jersey. " (4/11/2018)
- 2. Maxim Group analysts commented, "We are downgrading CGIX to Hold, from Buy and removing our price target following disappointing 4Q revenues, an increase in bad debt expense which was a surprise that leaves us with some concerns around the company’s ability to collect account receivables related to acquired testing platforms and/ or companies, and in our view, a lack of strategic direction of the company. 4Q17 revenue of $7.5M, up 4% y/y compared to the consensus estimate of $9.2M. Operating expenses in 4Q17 rose 82% and included $4.4M in bad debt expense." (4/3/2018)
Who are some of Cancer Genetics' key competitors?
Some companies that are related to Cancer Genetics include Brainstorm Cell Therapeutics (BCLI), Vascular Biogenics (VBLT), Sophiris Bio (SPHS), Axsome Therapeutics (AXSM), Navidea Biopharmaceuticals (NAVB), Obalon Therapeutics (OBLN), Five Star Senior Living (FVE), Arcturus Therapeutics (ARCT), Scynexis (SCYX), Vernalis (VNLPY), BioSig Technologies (BSGM), Versartis (VSAR), Pain Therapeutics (PTIE), Opiant Pharmaceuticals (OPNT), Rexahn Pharmaceuticals (RNN), Acerus Pharmaceuti (TRLPF), Zosano Pharma (ZSAN) and Abzena (ABZA).
Who are Cancer Genetics' key executives?
Cancer Genetics' management team includes the folowing people:
- Mr. John A. Roberts, Interim CEO & COO (Age 59)
- Dr. Raju S. K. Chaganti Ph.D., FACMG, Founder and Director (Age 85)
- Mr. Igor Gitelman CPA, MBA, Chief Accounting Officer (Age 42)
- Dr. Mandar Kulkarni Ph.D., Chief Technology Officer
- Mr. Cory Hickmon, VP of Bus. Devel. and Director of National Clinical Sales
Has Cancer Genetics been receiving favorable news coverage?
Headlines about CGIX stock have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cancer Genetics earned a media sentiment score of 0.21 on Accern's scale. They also assigned press coverage about the medical research company an impact score of 46.72 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Cancer Genetics?
Shares of CGIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cancer Genetics' stock price today?
One share of CGIX stock can currently be purchased for approximately $1.10.
How big of a company is Cancer Genetics?
Cancer Genetics has a market capitalization of $33.30 million and generates $29.12 million in revenue each year. The medical research company earns $-20,880,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Cancer Genetics employs 245 workers across the globe.
How can I contact Cancer Genetics?
Cancer Genetics' mailing address is 201 ROUTE 17 NORTH 2ND FLOOR, RUTHERFORD NJ, 07070. The medical research company can be reached via phone at 201-528-9200 or via email at [email protected]
MarketBeat Community Rating for Cancer Genetics (CGIX)
MarketBeat's community ratings are surveys of what our community members think about Cancer Genetics and other stocks. Vote "Outperform" if you believe CGIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cancer Genetics (NASDAQ:CGIX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Cancer Genetics in the last 12 months. Their average twelve-month price target is $6.00, suggesting that the stock has a possible upside of 445.45%. The high price target for CGIX is $6.00 and the low price target for CGIX is $6.00. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Buy | Buy | Buy |
| Consensus Rating Score: | 2.25 | 2.75 | 2.75 | 2.67 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.00 | $6.00 | $6.00 | $6.00 |
| Price Target Upside: | 445.45% upside | 233.33% upside | 200.00% upside | 110.53% upside |
Cancer Genetics (NASDAQ:CGIX) Consensus Price Target History
Cancer Genetics (NASDAQ:CGIX) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Cancer Genetics (NASDAQ:CGIX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Cancer Genetics (NASDAQ CGIX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 21.30%
Institutional Ownership Percentage: 17.94%
Cancer Genetics (NASDAQ CGIX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/15/2017 | John A Roberts | COO | Buy | 12,200 | $2.00 | $24,400.00 | 12,200 |  |
| 12/8/2017 | John Pappajohn | Director | Buy | 150,000 | $1.86 | $279,000.00 | 2,781,204 | |
| 8/18/2017 | John Pappajohn | Director | Buy | 86,185 | $3.24 | $279,239.40 | 2,608,704 | |
| 8/17/2017 | John Pappajohn | Director | Buy | 86,185 | $3.24 | $279,239.40 | 2,608,704 | |
| 6/12/2017 | John Pappajohn | Director | Buy | 100,000 | $3.75 | $375,000.00 | 2,542,519 | |
| 5/25/2017 | Igor Gitelman | Insider | Buy | 937 | $3.95 | $3,701.15 | 937 | |
| 5/23/2017 | Igor Gitelman | Insider | Sell | 937 | $4.02 | $3,766.74 | 937 | |
| 5/16/2017 | Geoffrey E Harris | Director | Buy | 2,500 | $3.75 | $9,375.00 | 22,500 | |
| 12/14/2016 | Geoffrey E Harris | Director | Buy | 2,500 | $1.50 | $3,750.00 | 20,000 | |
| 11/28/2016 | John Pappajohn | Director | Buy | 100,000 | $1.45 | $145,000.00 | 2,420,709 | |
| 11/16/2016 | Edward J Sitar | CFO | Sell | 3,333 | $1.56 | $5,199.48 | 14,167 | |
| 11/14/2016 | John Pappajohn | Director | Buy | 31,100 | $1.48 | $46,028.00 | 2,320,709 | |
| 8/16/2016 | John Pappajohn | Director | Buy | 45,000 | $2.29 | $103,050.00 | 2,287,109 | |
| 8/15/2016 | John Pappajohn | Director | Buy | 147,500 | $2.16 | $318,600.00 | 2,162,387 | |
| 3/17/2016 | John Pappajohn | Director | Buy | 50,000 | $2.64 | $132,000.00 | 1,771,789 | |
| 3/17/2016 | Panna Sharma | CEO | Buy | 1,500 | $2.59 | $3,885.00 | 152,000 | |
| 3/16/2016 | John Pappajohn | Director | Buy | 100,000 | $2.53 | $253,000.00 | 1,711,210 | |
| 3/15/2016 | Panna Sharma | CEO | Buy | 1,000 | $2.56 | $2,560.00 | 151,000 | |
| 8/27/2015 | John Pappajohn | Director | Buy | 5,000 | $9.61 | $48,050.00 | 1,519,289 | |
| 6/25/2015 | Raju S.K. Chaganti | Director | Sell | 5,296 | $12.00 | $63,552.00 | | |
| 6/12/2015 | Raju S.K. Chaganti | Director | Sell | 7,000 | $12.01 | $84,070.00 | | |
| 6/11/2015 | Raju S.K. Chaganti | Director | Sell | 46,454 | $12.03 | $558,841.62 | | |
| 6/8/2015 | Raju S.K. Chaganti | Director | Sell | 24,583 | $12.03 | $295,733.49 | | |
| 5/14/2015 | John Pappajohn | Director | Buy | 5,000 | $10.74 | $53,700.00 | | |
| 3/17/2015 | John Pappajohn | Director | Buy | 50,000 | $7.36 | $368,000.00 | | |
| 3/16/2015 | Edward J Sitar | CFO | Buy | 1,000 | $6.99 | $6,990.00 | | |
| 12/16/2014 | John Pappajohn | Director | Buy | 5,589 | $6.20 | $34,651.80 | | |
| 12/15/2014 | John Pappajohn | Director | Buy | 3,634 | $6.14 | $22,312.76 | | |
| 12/11/2014 | John Pappajohn | Director | Buy | 27,087 | $6.03 | $163,334.61 | | |
| 12/10/2014 | John Pappajohn | Director | Buy | 5,773 | $5.96 | $34,407.08 | | |
| 12/9/2014 | John Pappajohn | Director | Buy | 39,686 | $5.35 | $212,320.10 | | |
| 5/21/2014 | Edward Sitar | CFO | Buy | 1,000 | $10.67 | $10,670.00 | 1,000 | |
| 5/21/2014 | John Pappajohn | Director | Buy | 50,000 | $10.31 | $515,500.00 | 1,313,232 | |
(Data available from 1/1/2013 forward)
Cancer Genetics (NASDAQ CGIX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | CGIX LOSS NOTICE: Rosen Law Firm Reminds Cancer Genetics, Inc. Investors of Important Deadline in First Filed Case
finance.yahoo.com - April 21 at 5:19 PM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cancer Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline - CGIX
finance.yahoo.com - April 21 at 8:15 AM |
| SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Cancer Genetics, Inc. - CGIX
finance.yahoo.com - April 20 at 5:26 PM |
 | Cancer Genetics (CGIX) Research Coverage Started at Dawson James
www.americanbankingnews.com - April 20 at 3:01 PM |
| Pomerantz Law Firm Announces the Filing of a Class Action against Cancer Genetics, Inc. and Certain Officers – CGIX
finance.yahoo.com - April 18 at 5:49 PM |
| SHAREHOLDER INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Cancer Genetics, Inc. and Encourages Investors with Losses to Contact The Firm
finance.yahoo.com - April 17 at 8:22 AM |
| Today’s Research Reports on Stocks to Watch: Celldex Therapeutics and Cancer Genetics
finance.yahoo.com - April 17 at 8:22 AM |
 | FDA Gives Thumbs Up to Cancer Genetics' TOO Diagnostic Test
www.baystreet.ca - April 16 at 5:30 PM |
| Cancer Genetics’ Unique Tissue of Origin Test (TOO®) Receives Special FDA 510(k) Clearance
finance.yahoo.com - April 16 at 8:11 AM |
| Critical Contrast: Miragen Therapeutics (MGEN) versus Cancer Genetics (CGIX)
www.americanbankingnews.com - April 15 at 7:19 PM |
| ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cancer Genetics, Inc. and Encourages Investors with Losses to Contact The Firm
finance.yahoo.com - April 12 at 5:44 PM |
| Head to Head Review: Natera (NTRA) and Cancer Genetics (CGIX)
www.americanbankingnews.com - April 12 at 9:09 AM |
| Zacks Investment Research Downgrades Cancer Genetics (CGIX) to Sell
www.americanbankingnews.com - April 11 at 8:26 PM |
| Safirstein Metcalf LLP Announces That A Class Action Has Been Filed Against Cancer Genetics, Inc. – CGIX
finance.yahoo.com - April 11 at 5:37 PM |
| WOLF HALDENSTEIN: CANCER GENETICS, INC. INVESTOR ALERT - Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action has been filed against Cancer Genetics, Inc. in the United States District Court for the District of New Jersey
finance.yahoo.com - April 11 at 5:37 PM |
| Cancer Genetics, Inc. (CGIX) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 11 at 8:51 AM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cancer Genetics, Inc. - CGIX
finance.yahoo.com - April 10 at 5:33 PM |
| Free Research Report as DexCom’s Quarterly Revenues Surged 29%; Turned Profitable Y-O-Y
finance.yahoo.com - April 10 at 8:18 AM |
| Cancer Genetics (CGIX) Cut to Neutral at Dawson James
www.americanbankingnews.com - April 10 at 7:57 AM |
| IMPORTANT INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Cancer Genetics, Inc. and Encourages Investors with Losses to Contact The Firm
finance.yahoo.com - April 9 at 5:26 PM |
| SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Cancer Genetics, Inc. (CGIX) & Lead Plaintiff Deadline: June 4, 2018
finance.yahoo.com - April 9 at 5:26 PM |
 | UPDATE: Dawson James Downgrades Cancer Genetics, Inc. (CGIX) to Neutral
www.streetinsider.com - April 9 at 8:13 AM |
| CGIX INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Cancer Genetics, Inc. Investors
finance.yahoo.com - April 9 at 8:13 AM |
| Glancy Prongay & Murray LLP Continues Investigation on Behalf of Cancer Genetics, Inc. Investors (CGIX)
finance.yahoo.com - April 6 at 5:45 PM |
| Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Cancer Genetics, Inc. (CGIX) and Encourages Investors to Contact the Firm
finance.yahoo.com - April 6 at 5:45 PM |
| ONGOING INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Cancer Genetics, Inc. And Encourages Investors With Losses To Contact The Firm
finance.yahoo.com - April 6 at 5:45 PM |
| EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Cancer Genetics, Inc. – CGIX
finance.yahoo.com - April 6 at 8:19 AM |
| CGIX INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Cancer Genetics, Inc. Investors
finance.yahoo.com - April 5 at 5:21 PM |
| INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Cancer Genetics, Inc. And Encourages Investors With Losses To Contact The Firm
finance.yahoo.com - April 5 at 5:21 PM |
| IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cancer Genetics, Inc.
finance.yahoo.com - April 4 at 4:18 PM |
 | Cancer Genetics down 32% on material weakness disclosure and increased A/R
seekingalpha.com - April 3 at 5:39 PM |
| Cancer Genetics (CGIX) Downgraded by Maxim Group
www.americanbankingnews.com - April 3 at 11:00 AM |
| After-hours buzz: SWCH, VIAB, CVV & CGIX
finance.yahoo.com - April 3 at 8:16 AM |
 | Cancer Genetics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Strategic Business Updates
globenewswire.com - April 2 at 5:31 PM |
| Cancer Genetics misses by $0.24, misses on revenue
seekingalpha.com - April 2 at 5:31 PM |
 | Angelina Jolie shed light on a rare but potentially misleading mutation that ups your risk of breast cancer — and now ...
www.businessinsider.com - April 1 at 6:01 PM |
| Reviewing Cancer Genetics (CGIX) and Universal Health Services (UHS)
www.americanbankingnews.com - March 31 at 11:22 AM |
| Cancer Genetics (CGIX) PT Set at $6.00 by HC Wainwright
www.americanbankingnews.com - March 28 at 2:06 PM |
| Cancer Genetics to Host Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 26 at 8:16 AM |
| Cancer Genetics (CGIX) Upgraded at ValuEngine
www.americanbankingnews.com - March 25 at 7:32 PM |
| Analysts Anticipate Cancer Genetics Inc (CGIX) Will Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - March 25 at 1:18 PM |
| Cancer Genetics Inc (CGIX) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - March 17 at 7:30 AM |
| Cancer Genetics (CGIX) and HMS (HMSY) Head to Head Analysis
www.americanbankingnews.com - March 16 at 1:24 AM |
 | PierianDx Announces Partnership with Cancer Genetics to Provide Comprehensive Precision Oncology Testing and ... - Business Wire (press release)
www.businesswire.com - March 15 at 8:11 AM |
| Brokerages Anticipate Cancer Genetics Inc (CGIX) Will Post Quarterly Sales of $9.45 Million
www.americanbankingnews.com - March 10 at 9:26 AM |
| Zacks: Analysts Expect Cancer Genetics Inc (CGIX) Will Announce Earnings of -$0.11 Per Share
www.americanbankingnews.com - March 8 at 1:56 PM |
| Stonepine Capital Management LLC Takes Position in Cancer Genetics Inc (CGIX)
www.americanbankingnews.com - March 6 at 10:02 AM |
| $9.45 Million in Sales Expected for Cancer Genetics Inc (CGIX) This Quarter
www.americanbankingnews.com - February 21 at 4:32 AM |
| Cancer Genetics Inc (CGIX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 20 at 2:34 PM |
| Zacks: Brokerages Anticipate Cancer Genetics Inc (CGIX) Will Announce Earnings of -$0.11 Per Share
www.americanbankingnews.com - February 19 at 1:16 PM |
Cancer Genetics (NASDAQ:CGIX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cancer Genetics (NASDAQ:CGIX) Income Statement, Balance Sheet and Cash Flow Statement
Cancer Genetics (NASDAQ CGIX) Stock Chart for Saturday, April, 21, 2018
Loading chart…
